NO20075095L - Metode for fremstilling av salter av 4-[[5-[(cyklopropylamino)karbonyl]-2-Methylphenyl]Amino]-Methyl-N-Propylpyrrolo[2,1-F][1,2,4]triazin-6-karboksamid og nye stabile varianter av disse - Google Patents

Metode for fremstilling av salter av 4-[[5-[(cyklopropylamino)karbonyl]-2-Methylphenyl]Amino]-Methyl-N-Propylpyrrolo[2,1-F][1,2,4]triazin-6-karboksamid og nye stabile varianter av disse

Info

Publication number
NO20075095L
NO20075095L NO20075095A NO20075095A NO20075095L NO 20075095 L NO20075095 L NO 20075095L NO 20075095 A NO20075095 A NO 20075095A NO 20075095 A NO20075095 A NO 20075095A NO 20075095 L NO20075095 L NO 20075095L
Authority
NO
Norway
Prior art keywords
crystals
preparation
methyl
propylpyrrolo
cyclopropylamino
Prior art date
Application number
NO20075095A
Other languages
English (en)
Norwegian (no)
Inventor
Mary F Malley
Zhongping Shi
Soonjin Kim
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20075095L publication Critical patent/NO20075095L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
NO20075095A 2005-04-18 2007-10-09 Metode for fremstilling av salter av 4-[[5-[(cyklopropylamino)karbonyl]-2-Methylphenyl]Amino]-Methyl-N-Propylpyrrolo[2,1-F][1,2,4]triazin-6-karboksamid og nye stabile varianter av disse NO20075095L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67225505P 2005-04-18 2005-04-18
PCT/US2006/014504 WO2006113682A1 (en) 2005-04-18 2006-04-18 Process for preparing salts of 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-n-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide and novel stable forms produced therein

Publications (1)

Publication Number Publication Date
NO20075095L true NO20075095L (no) 2007-11-15

Family

ID=36693144

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075095A NO20075095L (no) 2005-04-18 2007-10-09 Metode for fremstilling av salter av 4-[[5-[(cyklopropylamino)karbonyl]-2-Methylphenyl]Amino]-Methyl-N-Propylpyrrolo[2,1-F][1,2,4]triazin-6-karboksamid og nye stabile varianter av disse

Country Status (12)

Country Link
US (3) US20060235020A1 (de)
EP (1) EP1874778B1 (de)
JP (1) JP5047160B2 (de)
CN (1) CN101198610B (de)
AR (1) AR053586A1 (de)
AT (1) ATE452894T1 (de)
DE (1) DE602006011295D1 (de)
ES (1) ES2336363T3 (de)
NO (1) NO20075095L (de)
PE (1) PE20061429A1 (de)
TW (1) TW200716126A (de)
WO (1) WO2006113682A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
PT1497019E (pt) * 2002-04-23 2015-09-10 Bristol Myers Squibb Co Compostos de pirrolotriazina anilina úteis como inibidores de quinase
JP2011503232A (ja) 2007-11-20 2011-01-27 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 免疫応答の調節
ES2539620T3 (es) 2008-12-19 2015-07-02 Cephalon, Inc. Pirrolotriazina como inhibidor de ALK y de JAK2
WO2012024489A2 (en) * 2010-08-18 2012-02-23 Emory University Compounds and compositions for ossification and methods related thereto
WO2012031057A1 (en) 2010-09-01 2012-03-08 Bristol-Myers Squibb Company Bms- 582949 for the treatment of resistant rheumatic disease
CN104003990B (zh) * 2013-02-21 2017-09-15 江苏先声药业有限公司 杂环胺类Hedgehog信号通路抑制剂
CN106068619B (zh) * 2014-01-24 2019-11-19 华为技术有限公司 用于进行交叉极化干扰抑制的方法和设备
US20180071376A1 (en) 2015-03-23 2018-03-15 The Brigham And Women`S Hospital, Inc. Tolerogenic nanoparticles for treating diabetes mellitus
GB2533833B (en) * 2015-06-22 2016-12-14 Univ Bristol Wireless ultrasound sensor with two induction coils
CN105651804B (zh) * 2016-03-11 2017-05-17 山西大学 一种慢性萎缩性胃炎大鼠模型的评价方法
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
BR112020006677A2 (pt) 2017-10-05 2020-10-06 Fulcrum Therapeutics, Inc. uso de inibidores p38 para reduzir a expressão de dux4
WO2020209868A1 (en) * 2019-04-12 2020-10-15 Bruker Axs, Inc. A system and method for diffraction-based structure determination with simultaneous processing modules

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200750A (en) * 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
IL118544A (en) * 1995-06-07 2001-08-08 Smithkline Beecham Corp History of imidazole, the process for their preparation and the pharmaceutical preparations containing them
PL187516B1 (pl) * 1996-01-11 2004-07-30 Smithkline Beecham Corp Nowe podstawione pochodne imidazolu, sposób ich wytwarzania oraz kompozycja farmaceutyczna zawierająca te związki
US6147080A (en) * 1996-12-18 2000-11-14 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US5945418A (en) * 1996-12-18 1999-08-31 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US6087496A (en) * 1998-05-22 2000-07-11 G. D. Searle & Co. Substituted pyrazoles suitable as p38 kinase inhibitors
IL132736A0 (en) * 1997-05-22 2001-03-19 Searle & Co 3(5)-Heteroaryl substituted pyrazoles as p38 kinase inhibitors
US6251914B1 (en) * 1997-07-02 2001-06-26 Smithkline Beecham Corporation Cycloalkyl substituted imidazoles
US6130235A (en) * 1998-05-22 2000-10-10 Scios Inc. Compounds and methods to treat cardiac failure and other disorders
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
PT1497019E (pt) * 2002-04-23 2015-09-10 Bristol Myers Squibb Co Compostos de pirrolotriazina anilina úteis como inibidores de quinase
MY145634A (en) * 2003-12-29 2012-03-15 Bristol Myers Squibb Co Pyrrolotriazine compounds as kinase inhibitors

Also Published As

Publication number Publication date
JP2008538373A (ja) 2008-10-23
DE602006011295D1 (de) 2010-02-04
EP1874778A1 (de) 2008-01-09
CN101198610A (zh) 2008-06-11
JP5047160B2 (ja) 2012-10-10
CN101198610B (zh) 2012-06-13
PE20061429A1 (es) 2006-12-17
TW200716126A (en) 2007-05-01
ES2336363T3 (es) 2010-04-12
US20120108594A1 (en) 2012-05-03
ATE452894T1 (de) 2010-01-15
US20090312331A1 (en) 2009-12-17
US20060235020A1 (en) 2006-10-19
EP1874778B1 (de) 2009-12-23
WO2006113682A1 (en) 2006-10-26
AR053586A1 (es) 2007-05-09

Similar Documents

Publication Publication Date Title
NO20075095L (no) Metode for fremstilling av salter av 4-[[5-[(cyklopropylamino)karbonyl]-2-Methylphenyl]Amino]-Methyl-N-Propylpyrrolo[2,1-F][1,2,4]triazin-6-karboksamid og nye stabile varianter av disse
CA2422708A1 (en) 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
CN104936961B (zh) (1s,4s,5s)-4-溴-6-氧杂二环[3.2.1]辛-7-酮的制备方法
WO2020140005A8 (en) 1h-pyrrolo[2,3-b]pyridine derivatives and related compounds as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases
NO20064003L (no) Nyekarboksamider for anvendelse som XA-inhibitorer
CA2578122A1 (en) Pyrimidine derivatives
RU2639149C2 (ru) Кристаллический полиморф 4-[5-(пиридин-4-ил)-1н-1,2,4-триазол-3-ил]-пиридин-2-карбонитрила и способ его получения
PH12013500157A1 (en) SALT FORMS OF 4-(4-METHYLPIPERAZIN-1-YLMETHYL)-n-[4-METHYL-3-(4-PYRIDIN-3-YL)PYRIMIDIN-2-YLAMINO)PHENYL]-BENZAMIDE
JP2004518763A5 (de)
ATE401066T1 (de) Methoden zur behandlung der essstörungen
NO20073114L (no) Amidforbindelse
NO20054206L (no) Bifenylderivater
CA2680246A1 (en) Piperazinyl-propyl-pyrazole derivatives as dopamine d4 receptor antagonists, and pharmaceutical compositions containing the same
NO20062954L (no) Pyrazolylderivater i form av legemidler for behandling av av akutt eller kronisk neuronal regresjon
WO2015096604A1 (zh) 一种米拉贝隆有关物质或其盐、其制备方法和用途
NO20052683L (no) Nye pyridopyrimidinonforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
Darwish et al. Development of novel 2, 4-bispyridyl thiophene–based compounds as highly potent and selective Dyrk1A inhibitors. Part I: benzamide and benzylamide derivatives
Wang et al. Synthesis and antifungal activity evaluation of novel substituted pyrimidine‐5‐carboxamides bearing the pyridine moiety
CA2653666A1 (en) Aryl-substituted heterocycles and their use
EP0343307A1 (de) 4-Piperidinalkanamin-Derivate
TW200733882A (en) Method for controlling rust infections in leguminous plants
NO20042732L (no) Krystallinsk venlafaksin-base og nye polymorfe former av venlafaksin-hydroklorid samt fremgangsmater for fremstilling derav
NO20073548L (no) Fremstillingsprosess for N-substituerte salicylamider
AU605228B2 (en) Sweetening agents derived from guanidinoacetic and ethanamidinoacetic acids, process for sweetening various products, and compositions containing such sweetening agents
JPH07506585A (ja) 新規なジヒドロキシベンジルアミン誘導体，それらの製造およびそれらを含有している薬学的組成物

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application